Study #2020-0329
A Multi-Center Phase I study of AIC100 in Relapsed and/or Refractory Advanced Thyroid Cancer and Anaplastic Thyroid Cancer
MD Anderson Study Status
Enrolling
Treatment Agent
AIC100 CAR T Cells
Description
The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer
Study phase:
Phase I
Physician name:
Samer Srour
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-888-448-0874
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.